Description

Simple

Clinical

Overview

Canertinib is a pan-erbB tyrosine kinase inhibitor which work against esophageal squamous cell carcinoma in vitro and in vivo. Canertinib treatment significantly affects tumour metabolism, proliferation and hypoxia as determined by PET.

Pharmacology

Indication

Investigated for use/treatment in breast cancer and lung cancer.

Pharmacodynamic

Information currently not available.

Mechanism of action

CI-1033 effectively inhibits the growth of esophageal squamous cell carcinoma which co-expresses both EGFR and HER2 with the inhibition of phosphorylation of both MAPK and AKT. Some studies suggest that CI-1033 holds significant clinical potential in esophageal cancer.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Canertinib
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
3,5-diiodothyropropionic acid
The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Canertinib.
3,5-Diiodotyrosine
The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Canertinib.
Abaloparatide
The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Canertinib.
Acetaminophen
The serum concentration of Acetaminophen can be increased when it is combined with Canertinib.
Benzylthiouracil
The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Canertinib.
Carbimazole
The therapeutic efficacy of Carbimazole can be decreased when used in combination with Canertinib.
Darbepoetin alfa
The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Canertinib.
Dibromotyrosine
The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Canertinib.
Elcatonin
The therapeutic efficacy of Elcatonin can be decreased when used in combination with Canertinib.
Erythropoietin
The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Canertinib.
Follitropin
The therapeutic efficacy of Follitropin can be decreased when used in combination with Canertinib.
Levothyroxine
The therapeutic efficacy of Levothyroxine can be decreased when used in combination with Canertinib.
Liothyronine
The therapeutic efficacy of Liothyronine can be decreased when used in combination with Canertinib.
Liotrix
The therapeutic efficacy of Liotrix can be decreased when used in combination with Canertinib.
Methimazole
The therapeutic efficacy of Methimazole can be decreased when used in combination with Canertinib.
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Canertinib.
Methylthiouracil
The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Canertinib.
Parathyroid hormone
The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Canertinib.
Peginesatide
The risk or severity of Thrombosis can be increased when Peginesatide is combined with Canertinib.
Potassium Iodide
The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Canertinib.
2 References
  1. 1 . Simon GR, Garrett CR, Olson SC, Langevin M, Eiseman IA, Mahany JJ, Williams CC, Lush R, Daud A, Munster P, Chiappori A, Fishman M, Bepler G, Lenehan PF, Sullivan DM: Increased bioavailability of intravenous versus oral CI-1033, a pan erbB tyrosine kinase inhibitor: results of a phase I pharmacokinetic study. Clin Cancer Res. 2006 Aug 1;12(15):4645-51.PubMed: 16899614
  2. 2 . Sequist LV: Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist. 2007 Mar;12(3):325-30.PubMed: 17405897